About the role

Do you want to develop prenatal diagnostics that can affect the lives of millions of expecting parents? BillionToOne (Y Combinator S17) is looking for a Staff Software Engineer. We apply bioengineering and machine learning principles to diagnostics in order to build truly quantitative molecular tests. Our QCT platform improves resolution of cell-free DNA testing by >1000x fold and enables novel tests for both prenatal and oncology care.

If you have experience in full stack development, love seeing your work positively affect your colleagues, and thrive in a fast-paced entrepreneurial environment, this could be a great opportunity for you.

Who you are:

At least 6 years experience in professional software development
Very strong knowledge of using a dynamic programming language in production (e.g. python, ruby, javascript)
Experience working on both backend and frontend systems
Experience with cloud infrastructure such as AWS
Proven track record of shipping software

Nice to haves:

Prior work experience at a growth startup

Responsibilities:

One-on-one technical leadership: Code review, pair programming, individual mentorship, hiring.
Systems and process leadership: devops playbooks, CI+CD, defining testing environments and practices.
Writing and coordinating: System design, setting technical milestones, coordinating dependencies / critical path with other eng. teams.
Individual contributions.

About BillionToOne

Do you want to join one of the fastest-growing molecular diagnostics companies to help transform prenatal and oncology diagnostics that can affect millions of patient lives?

BillionToOne, one of the top Y Combinator companies with $200M+ in funding from prominent VC firms, has developed a DNA molecular counter that increases the cell-free DNA diagnostics resolution by over 1,000 fold. We are the only technology platform that can detect single-gene disorders in an unborn baby from maternal blood and that can accurately quantify tumor DNA changes in cancer patients.

UNITY Screen, our prenatal test, continues to grow exponentially and is on its path to becoming the next standard-of-care, with an increasing number of publications showing its accuracy and advantages over other screening methods. We have also recently used our molecular counting technology to develop liquid biopsy products, which will transform oncology care.